Pet Health Supplement OEM with Oral Dissolvable Films

Novohope is a pet health supplement manufacturer and OEM/ODM partner based in Wuxi, Jiangsu Province, China, operating under Wuxi Novohope Biotechnology Co., Ltd. The company was established in September 2025 and specializes in oral dissolvable film (ODF) and orally disintegrating tablet (ODT) formats for functional pet nutrition. It reports an export ratio of 95% and lists its primary markets as Europe, America, Britain, the Middle East, Japan, and South Korea.

Why Pet Supplement Brands Are Reconsidering Delivery Formats

For many pet owners, the bottleneck is not ingredient choice but administration. Cats and dogs frequently refuse pills, capsules, and powders, and forced feeding can create stress that works against a supplement's intended benefit. Oral films address this by dissolving on contact with saliva, but the format also needs a manufacturer with serious formulation expertise.

Market data supports the timing. According to Grand View Research, the global pet supplements market is valued at approximately USD 2.8 billion in 2025, with projected growth to USD 4.6 billion by 2033. The same report states that North America accounts for 48.1% of global revenue share. Mordor Intelligence identifies Asia-Pacific as the fastest-growing region, driven by rising pet humanization and healthcare expenditure in China and India.

Oral dissolvable film technology is now appearing in pet-sector benchmarks. According to Market Reports World, innovations in oral dissolving films focus on disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%. For OEM buyers, that trajectory makes fast-dissolve films a credible alternative to traditional supplements rather than a novelty.

Pet Supplement Oral Dissolvable Films: An OEM Opportunity

Novohope's OEM/ODM model is built around this format transition. The manufacturer offers brand agency, distribution, and OEM/ODM production services globally, with customization covering recipe, brand, packaging design, and other customized requirements. For brands evaluating a fast-dissolve film OEM for a pet line, the relevant question is not whether the format works, but whether the supplier can control formulation, compliance, and scale.

Novohope's Oral Film Manufacturing and Product Platform

Novohope's core technology is an oral melting film described as a film the size of a postage stamp. When in contact with pet saliva, it melts within 10 seconds, allowing active ingredients to enter the circulatory system through the oral mucosa. The company reports an absorption rate of up to 95%, compared with approximately 35% for traditional products, and states that the format is adapted to short pet intestines of less than 1.2 meters and stomach acid pH values of 1-3.

The product platform includes seven series designs: COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, and Fit+. Each is available in ODF or ODT formats. The table below lists the series as described in company product records.

The combination of ODF and ODT gives brand owners two fast-dissolve routes: a thin film for functions that benefit from rapid mucosal absorption, and an orally disintegrating tablet for formulations that prefer a compact solid format.

Technical Mechanism: Fast-Dissolve Film R&D for Pet Supplements

Novohope's R&D team of 12 engineers works on oral fast-dissolving matrices. The company's technical team comes from the Wahsheer Biotechnology Laboratory at the Chinese University of Hong Kong, and its core team includes people with experience in listed companies and biomedicine. This background matters for OEM clients because oral film R&D for pet supplements requires expertise in polymer selection, taste masking, stability, and dose uniformity.

The technical rationale for oral mucosal absorption is straightforward. Traditional oral medications pass through the stomach and intestines, where high acidity and short digestive tracts can affect active ingredients. In dogs and cats, the digestive route is especially short; the company describes pet intestines as less than 1.2 meters and stomach acid as pH 1-3. An oral film that dissolves in 10 seconds and absorbs through the oral mucosa bypasses part of that degradation pathway.

OEM/ODM Capabilities, MOQ, Lead Time, and Quality Control

Novohope's commercial terms are defined for evaluation-stage buyers. The manufacturer lists brand agency, distribution, and OEM/ODM production services as its operating modes, and its OEM/ODM program carries a standard MOQ of 3,000 units per SKU and a lead time of 35-45 days. Monthly capacity is reported at 200,000,000 units, and annual output at 200,000,000 boxes.

Quality control follows a documented sequence: 100% full inspection before delivery, plus third-party authoritative sampling testing. After-sales support is provided through remote support. Procurement support records also include flexible commercial terms depending on order type.

For buyers comparing suppliers, the factory-level facts are also relevant. Novohope operates a 20,000 m² facility in Wuxi and employs a team of 25, including a 12-engineer R&D team. The company reports an annual output capacity of 200,000,000 boxes and a monthly capacity of 200,000,000 units.

Compliance Evidence and Registration Status

Novohope completed FDA food registration for all products in July 2026 and obtained GS1 international product codes. The company also holds SDS and COA documentation and has established a global compliance and quality control system, according to its company records.

The specific documents available include an FDA Food Facility Registration certificate with number 18753066908, issued by the U.S. Food and Drug Administration on July 1, 2026, with validity listed to December 31, 2026. Product-level test reports include COAT+ Coat Care and Shiny Hair under certificate DTI2026EC050626-1, EYES+ Eye Care and Tear Stain Care under US FDA 21 CFR 175.300 with certificate DTI2026EC050626-2-2, and HEART+ Cardiovascular Care under certificate DTI2026EC050626-4. These reports were issued by Shenzhen Deesev Testing International Corporation in July 2026.

The company also holds trademark application acceptance notices from China's National Intellectual Property Administration in classes 7 and 31, issued February 12, 2026.

Use Cases: Retail Private Label, Tear Stain Care, and Functional Categories

Novohope's case records include a private label production and ODM customized formula development program for clients in Germany, the United Arab Emirates, Canada, Australia, France, and the United States. The order volume is recorded as 200,000 units, with application in chain supermarkets and retail stores over a three-year period. The reported result was a significant increase in pet health category sales and stable repeat orders, with highlights described as green safety, ease of use, and low pet resistance.

For tear stain formula pet supplements, the market signal is strong. ASINSIGHT reports that top-selling dog tear stain supplements on major e-commerce platforms can reach monthly volumes of 100,000 units, with growth driven by antioxidant blends such as Lutein, Zeaxanthin, and Astaxanthin. Novohope's EYES+ series is positioned in the eye care and tear stain category as an ODF format, making it a relevant reference for retailers considering a private-label tear stain product.

Beyond eye care, the platform covers the main functional pet supplement demand clusters: coat and skin (COAT+), calming and stress relief (CALM+), joint care and mobility (BONE+), cardiovascular support (HEART+), digestive care (PROBIO), and weight management (Fit+).

Market Trends Behind Oral Film Adoption

The verified market data points to a category still in early format transition. The global pet supplements market is projected to grow from USD 2.8 billion in 2025 to USD 4.6 billion by 2033, according to Grand View Research. North America holds 48.1% of the market, while Asia-Pacific is the fastest-growing region, according to Mordor Intelligence.

Within North America, the NASC Quality Seal is a recognized industry standard requiring GMP adherence and labeling audits, according to the National Animal Supplement Council. For OEM buyers, this puts compliance documentation at the center of supplier qualification.

ODF technology benchmarks add another layer. Market Reports World describes oral dissolving film innovations centered on sub-25-second disintegration and palatability gains of up to 47%. Novohope's product records align with that direction, with films designed to dissolve in about 10 seconds and absorb through the oral mucosa.

Oral Films vs. Traditional Pet Supplement Formats

Compared with tablets, capsules, powders, and liquid drops, oral films change three variables: administration, absorption, and stress. There is no swallowing step, active ingredients can enter the bloodstream through the oral mucosa, and the format is easier to give to a reluctant pet. The trade-off appears in formulation scope.

Not all ingredient profiles fit an oral film matrix. High-dose actives, large-volume formulas, and compounds sensitive to film drying or polymer compatibility may require reformulation or a different format such as an ODT. This is a genuine limitation, and it is the main reason a manufacturer needs R&D depth rather than filling lines alone.

Future Outlook for Pet Supplement Oral Film OEM

Novohope's first-year milestones show how quickly the oral film segment can move. The company was established in September 2025, presented six products at the International Pet Exhibition in Nuremberg, Germany, in May 2026, received more than 700 visitors and reached over 100 potential clients, and opened a new R&D and marketing center in Shekou, Shenzhen, in June 2026. By July 2026, all products had completed FDA food registration and obtained GS1 codes.

For brands, the outlook is practical: expect oral film procurement conversations to center on stability data, target-market registration, and dosage-form compatibility. With North America as the largest market and Asia-Pacific growing fastest, a supplier with documented export compliance and multi-format capabilities is better positioned for retail programs across both regions.

FAQ